预约演示
更新于：2025-06-13
Eldecalcitol
艾地骨化醇
更新于：2025-06-13
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (2011-01-21), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C30H50O5 |
InChIKeyFZEXGDDBXLBRTD-AYIMTCTASA-N |
CAS号104121-92-8 |
关联
61
项与 艾地骨化醇 相关的临床试验CTR20250960
艾地骨化醇软胶囊在中国成年健康受试者中的一项随机、开放、空腹和餐后单次给药、两制剂、两序列、两周期交叉的生物等效性研究
CTR20244662
艾地骨化醇软胶囊人体生物等效性研究
CTR20243090
艾地骨化醇软胶囊（0.75μg）在健康受试者中空腹和餐后状态下单中心、随机、开放、单剂量、两制剂、两周期、两序列、自身交叉的生物等效性试验
100 项与 艾地骨化醇 相关的临床结果
登录后查看更多信息
100 项与 艾地骨化醇 相关的转化医学
登录后查看更多信息
100 项与 艾地骨化醇 相关的专利（医药）
登录后查看更多信息
413
项与 艾地骨化醇 相关的文献（医药）2025-07-01CELLULAR SIGNALLING
ED-71 ameliorates OVX-induced osteoporosis by regulating calcium homeostasis and SIRT1-mediated mitochondrial function, alleviating osteoblast senescence and suppressing osteoclastogenesis
Article
作者: Guo, Jie ; Cui, Yajun ; Sun, Changyun ; Zhang, Yaoguang ; Li, Minqi
Osteoporosis arising from estrogen deficiency is characterized by oxidative stress and cellular senescence accompanied by calcium loss and disrupted bone metabolism. The paracrine interaction between osteoblasts and osteoclasts, along with the ratio of receptor activator of nuclear factor-κB ligand (RANKL) to osteoprotegerin (OPG), play a pivotal role in maintaining bone homeostasis. Eldecalcitol (ED-71), a novel active form of vitamin D, can reduce the ratio of RANKL to OPG in osteoblasts. In this study, an ovariectomized (OVX) rat model was established in vivo, and a cell model was constructed in vitro using H₂O₂ to explore the specific mechanism by which ED-71 improved the release of RANKL/OPG in senescent osteoblasts. Mitochondrial dysfunction and calcium imbalance were identified as significant factors. Under oxidative stress conditions, ED-71 alleviated endoplasmic reticulum (ER) stress by decreasing the ratio of phosphorylated protein kinase R-like ER kinase (P-PERK/PERK), and augmented the expression levels of sarcoplasmic reticulum/endoplasmic reticulum calcium ATPase 2 (SCERA2) thereby promoting calcium uptake by the ER, enhancing ER calcium influx, and effectively ameliorating calcium homeostasis between the ER and mitochondria. Consequently, it mitigates mitochondrial calcium overload and associated dysfunction. In contrast, ED-71 increased the expression of silent information regulator 1 (SIRT1) and phosphorylated AMP-activated protein kinase (P-AMPK). This alleviates mitochondrial dysfunction and promotes adenosine triphosphate (ATP). The combined effects of these two factors synergistically contribute to the improvement in osteoblast senescence.
2025-07-01METABOLISM-CLINICAL AND EXPERIMENTAL
Anti-sarcopenic effects of active vitamin D through modulation of anabolic and catabolic signaling pathways in human skeletal muscle: A randomized controlled trial
Article
作者: Toda, Mikio ; Tominaga, Naoki ; Kawahara, Tetsuya ; Mizuno, Shoichi ; Inazu, Tetsuya ; Kawahara, Chie ; Suzuki, Gen ; Toyama, Nagahiro
BACKGROUND:
The muscle-building and strengthening effects of the active form of vitamin D in humans remain unclear.
METHODS:
In this ancillary study of the Diabetes Prevention with active Vitamin D trial, we examined clinical and experimental aspects to investigate the effects and mechanisms of eldecalcitol, an active form of vitamin D, in preventing sarcopenia. We examined changes in molecules involved in muscle synthesis and degradation pathways in muscle samples from 32 participants before and after 1 year of eldecalcitol or placebo treatment. The protein levels of molecules involved in muscle synthesis and degradation pathways were examined using western blotting. Additionally, the skeletal muscle and body fat volumes were measured using bioelectrical impedance analysis with a body composition analyzer.
RESULTS:
We found that eldecalcitol treatment for 1 year resulted in higher phosphorylation levels of mTOR and FOXO1 signaling pathways, which are associated with increased muscle mass and strength than those with placebo treatment. Body composition measurements at 1 year showed that the eldecalcitol group had significantly higher skeletal muscle mass (1.9 % vs. -3.4 %, p = 3.26E-9) and muscle strength (4.1 % vs. -0.7 %, p = 2.57E-17), and lower fat mass (-3.2 % vs. 1.8 %, p = 1.73E-12) than those in the placebo group.
CONCLUSION:
This study suggested that the active form of vitamin D regulates the protein synthesis and degradation pathways in human skeletal muscle and may help prevent sarcopenia. This study was registered at UMIN clinical trials registry, UMIN 000005394.
2025-04-01YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN
Changes in the Serum Calcium Level and Renal Function After Switching from Alfacalcidol to Eldecalcitol
Article
作者: Noda, Kouhei ; Nagae, Hiroko ; Kamimura, Hidetoshi ; Hagiwara, Daiki ; Kaneshige, Susumu ; Nagai-Nakamura, Haruka
Active vitamin D3 (VDRAs) can cause drug-induced hypercalcemia and acute renal failure. Eldecalcitol (ELD), a VDRA, promotes bone formation more strongly than other VDRAs, such as alfacalcidol (ALF), but whether or not ELD affects serum calcium (Ca) levels and renal function more significantly than other VDRAs is unclear. In Japan, the supply of ALF was temporarily stopped in 2021, and patients at Fukuoka University Hospital who were taking ALF were either switched to ELD or discontinued ALF. We retrospectively investigated how these prescription changes affected serum Ca levels and renal function. Sixty-seven adult patients who were admitted to our hospital for at least 5 d between September 2021 and March 2022 and were taking ALF at the time of admission were divided into 3 groups: 36 patients who continued ALF (ALF-C), 12 who were switched to ELD (ELD-S), and 19 who discontinued VDRAs (DC). The changes in weekly serum Ca levels and renal function during hospitalization were compared between the groups. At the second week of observation, the change in the serum Ca level was 0.01 mg/dL in the ALF-C group, +0.45 mg/dL in the ELD-S group, and -0.37 mg/dL in the DC group, showing a significant difference among these groups. In addition, serum Ca levels were increased in all patients in the ELD-S group at Week 2. The estimated glomerular filtration rate didn't change significantly in any group during hospitalization. These results suggest that serum Ca levels should be measured by Week 2 when ELD is newly started or changed.
100 项与 艾地骨化醇 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 骨质疏松症 | 日本 | 2011-01-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 原发性骨质疏松症 | 临床3期 | 中国 | 2015-08-31 | |
| 骨质疏松性骨折 | 临床3期 | - | 2004-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | (Tail Suspension) | 襯窪蓋壓觸鬱憲網襯鏇(繭齋築壓築繭構網積淵) = Bone loss as indicated by increase of 45.8% in BS/BV was partially rescued by ELD 範衊簾繭夢選壓鬱鏇淵 (齋鹹簾壓醖鏇膚範積壓 ) 更多 | 积极 | 2023-05-04 | ||
N/A | - | - | 鏇獵鬱鹽窪餘鬱築鹽網(選糧繭觸繭窪艱艱糧憲) = 鹽築範壓窪觸廠醖構構 築觸窪積艱鹹網齋構獵 (鹹製廠鹹憲觸獵簾襯範 ) | 不佳 | 2016-11-15 | ||
Placebo | 鏇獵鬱鹽窪餘鬱築鹽網(選糧繭觸繭窪艱艱糧憲) = 蓋簾壓窪遞鹽觸壓衊廠 築觸窪積艱鹹網齋構獵 (鹹製廠鹹憲觸獵簾襯範 ) | ||||||
N/A | - | - | 鏇窪壓膚醖觸網構淵網(鏇遞窪鹹範觸憲觸艱窪) = 構顧膚衊淵襯願膚網獵 糧艱獵艱艱鬱鬱鬱網醖 (繭鹽獵壓窪蓋廠鑰憲鏇 ) | 积极 | 2014-05-01 | ||
鏇窪壓膚醖觸網構淵網(鏇遞窪鹹範觸憲觸艱窪) = 壓顧顧積餘餘廠齋鑰廠 糧艱獵艱艱鬱鬱鬱網醖 (繭鹽獵壓窪蓋廠鑰憲鏇 ) | |||||||
临床3期 | 1,054 | 鬱廠選鏇淵顧蓋選廠餘(餘簾衊鹹膚範鹹襯製艱) = 憲簾鏇願簾淵選鹹餘獵 襯醖遞觸觸範築鑰鬱艱 (願範襯構網選餘衊餘蓋, 0.56 ~ 0.97) | 积极 | 2011-10-01 | |||
鬱廠選鏇淵顧蓋選廠餘(餘簾衊鹹膚範鹹襯製艱) = 製艱積繭構夢觸觸遞鏇 襯醖遞觸觸範築鑰鬱艱 (願範襯構網選餘衊餘蓋 ) | |||||||
N/A | - | 廠築繭窪鹽夢艱鏇衊鬱(艱襯獵鹹餘鏇蓋齋憲選) = 餘壓壓廠壓衊網網鏇構 淵範衊淵鹽選觸選獵壓 (選願繭願齋鑰築鏇淵遞 ) | - | 2010-11-16 | |||
廠築繭窪鹽夢艱鏇衊鬱(艱襯獵鹹餘鏇蓋齋憲選) = 願鹹鏇簾壓壓鹹構構鬱 淵範衊淵鹽選觸選獵壓 (選願繭願齋鑰築鏇淵遞 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用